logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • United Therapeutics Corporation drugs

    FiltersReset Filters
    6 results

    • adcirca

      (Tadalafil)
      United Therapeutics Corporation
      Usage: ADCIRCA® is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise ability, specifically in patients with NYHA Functional Class II-III symptoms, including idiopathic, heritable PAH, and PAH associated with connective tissue diseases.

    • orenitram

      (treprostinil)
      United Therapeutics Corporation
      Usage: Orenitram is indicated for treating pulmonary arterial hypertension (PAH) to delay disease progression and improve exercise capacity, primarily in patients with WHO functional class II-III symptoms, including idiopathic, heritable, or connective tissue disease-associated PAH.

    • remodulin

      (treprostinil)
      United Therapeutics Corporation
      Usage: Remodulin is used to treat pulmonary arterial hypertension (PAH) to alleviate symptoms during exercise in patients with NYHA Functional Class II-IV. It is also indicated for those transitioning from epoprostenol to reduce clinical deterioration. Indications include idiopathic, heritable PAH, congenital shunts, and connective tissue diseases.

    • tyvaso

      (treprostinil)
      United Therapeutics Corporation
      Usage: Tyvaso is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise ability in patients, especially those with NYHA Functional Class III symptoms. It is also approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD), enhancing exercise capacity in affected patients.

    • tyvaso dpi

      (treprostinil)
      United Therapeutics Corporation
      Usage: Tyvaso DPI is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in patients, particularly those with NYHA Functional Class III symptoms. It is also indicated for pulmonary hypertension associated with interstitial lung disease (PH-ILD) to enhance exercise capacity.

    • unituxin

      (DINUTUXIMAB)
      United Therapeutics Corporation
      Usage: Unituxin (dinutuximab) is indicated for pediatric patients with high-risk neuroblastoma who show at least a partial response to prior multiagent therapy. It is used in combination with GM-CSF, IL-2, and 13-cis-retinoic acid for treatment.